Amgen, Array BioPharma Enter Collaboration
Amgen and Array BioPharma, a Boulder, Colorado-based biopharmaceutical company developing small-molecule anti-cancer therapies, have formed a collaboration agreement for the discovery and development of drugs for autoimmune disorders.
The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early-lead development.
Under this agreement, Amgen and Array will collaborate on preclinical development with Array leading the medicinal chemistry work. Amgen is responsible for clinical development and commercialization. In exchange for exclusive rights to Array’s preclinical program, Amgen will make upfront and milestone payments as well as pay royalties on sales of resulting therapies.